01 / Research notes
What recovery searches are asking
People searching for TB-500 often have a wound, tendon injury, or persistent pain. Those problems have different causes and treatment pathways. An apparent delay in healing can reflect infection, circulation, diabetes, or another issue that needs direct evaluation.
Preclinical tissue-repair signals are research hypotheses, not a measured benefit in people using a compounded TB-500 preparation.
02 / Research notes
Why thymosin beta-4 results do not transfer
TB-500 is a seven amino-acid fragment associated with thymosin beta-4. Studies of the full protein, including work outside musculoskeletal care, cannot establish biological or clinical equivalence. A recent clinical review found no controlled human orthopedic efficacy evidence for TB-500.
Product identity also matters: commercial labels may not show whether the tested substance matches the one described in a study.
03 / Research notes
Benefit and risk together
A convincing clinical claim would require a defined formulation, controlled human outcomes, and enough follow-up to measure harms. Those data are not available for wound or injury claims.
FDA has highlighted potential immune-response, aggregation, and impurity concerns. HHS's interim policy is conditional compounding enforcement discretion, not FDA approval or a finding of benefit.
Common questions
Does TB-500 speed recovery?
That outcome has not been established in controlled human studies of a TB-500 product.
Is TB-500 the same as thymosin beta-4?
No. The fragment and full protein are distinct; findings cannot be transferred automatically.
Is TB-500 approved for wound healing?
No. TB-500 is not an FDA-approved wound-healing drug.
Are TB-500 benefits different for women and men?
No reliable human evidence establishes sex-specific recovery benefits.
Sources and important information
Compounded drugs are not FDA approved and have not undergone FDA review for safety, effectiveness, or quality before marketing. HHS's interim policy is conditional and may change. Treatment through Jonathan Larson MDPC requires clinical evaluation; a licensed provider decides whether any prescription is medically necessary and appropriate. This guide is informational, not medical advice.